Sernova's CEO Dr. Philip Toleikis Featured on BNN

Sernova's CEO Dr. Philip Toleikis Featured on BNN
  
 

LONDON, ONTARIO--(Marketwired - Jun 20, 2014) - Sernova Corp. (TSX-VENTURE:SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia today was featured on BNN by news anchor Francis Horodelski.

Please refer to the segment using the following link:

http://www.bnn.ca/Video/player.aspx?vid=384318

About Sernova

Sernova Corp. is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch™, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary technologies.

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sernova Corp.Philip Toleikis, Ph.D.President and CEO(604) [e-mail] / [e-mail] Matthews & AssociatesRay Matthews(604) 818-7778www.raymatthews.ca